{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2022_00025264", "CSN": null, "TRF": "ORD_1517889_01", "MRN": "14285575", "PhysicianId": "109266", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1233882", "clinicalId": "1235252", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1517889_01", "SampleName": "US1452511.01", "Version": "0", "Sample": {"FM_Id": "ORD_1517889_01", "SampleId": "US1452511.01", "BlockId": "nan", "TRFNumber": "ORD_1517889_01", "TestType": "FoundationOne Liquid  ", "SpecFormat": "Blood", "ReceivedDate": "2022_12_05", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}]}, "TumorPurity": "Elevated Tumor Fraction Not Detected", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "M111-10033", "MRN": "14285575", "FullName": "\u7c21\u6587\u9e9f", "FirstName": "Wen_Lin", "LastName": "Chien", "SubmittedDiagnosis": "HPV-positive carcinoma", "Gender": "Male", "DOB": "1971_12_10", "OrderingMD": "\u9673\u5929\u83ef", "OrderingMDId": "109266", "Pathologist": "\u9673\u5fd7\u5b78", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Blood", "CollDate": "2022_12_01", "ReceivedDate": "2022-12-15 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Head and Neck Squamous Cell Carcinoma"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "19", "clinicalTrialCount": "10", "resistiveCount": "0", "sensitizingCount": "3"}, "VariantProperties": {"VariantProperty": [{"geneName": "APC", "isVUS": "true", "variantName": "V1125A"}, {"geneName": "CARD11", "isVUS": "true", "variantName": "S694L"}, {"geneName": "CD22", "isVUS": "true", "variantName": "S230P"}, {"geneName": "CREBBP", "isVUS": "true", "variantName": "S908I"}, {"geneName": "EGFR", "isVUS": "true", "variantName": "D800V"}, {"geneName": "EPHA3", "isVUS": "true", "variantName": "H61Q"}, {"geneName": "FGF6", "isVUS": "true", "variantName": "L3M"}, {"geneName": "FGFR1", "isVUS": "true", "variantName": "P469S"}, {"geneName": "IRS2", "isVUS": "true", "variantName": "A512T"}, {"geneName": "MAP3K1", "isVUS": "true", "variantName": "L78P"}, {"geneName": "NTRK3", "isVUS": "true", "variantName": "G547R"}, {"geneName": "PALB2", "isVUS": "true", "variantName": "S652N"}, {"geneName": "PDCD1LG2 (PD_L2)", "isVUS": "true", "variantName": "Y106C"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "NF1", "Include": "true", "Alterations": {"Alteration": {"Name": "I679fs*21", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "0.99", "isEquivocal": "false", "name": "I679fs*21"}}, "Interpretation": "NF1 encodes neurofibromin, a GTPase_activating protein (GAP) that is a key negative regulator of the RAS signaling pathway (Hattori et al., 1991; 1904223). Neurofibromin acts as a tumor suppressor by repressing RAS signaling (Morcos et al., 1996; 8628317). Alterations such as seen here may disrupt NF1 function or expression (Ballester et al., 1990; 2121371, Xu et al., 1990; 2116237, Martin et al., 1990; 2121370, Thomas et al., 2012; 22807134, Skuse and Cappione, 1997; 9300663, Morcos et al., 1996; 8628317, Messiaen et al., 1999; 11258625, Ars et al., 2000; 10607834, Messiaen and Wimmer, 2005; 15863657, Poullet et al., 1994; 8264648). NF1 alterations are common in various solid tumors, with mutations being more frequent than gene loss, and are often seen in melanoma (18%), glioma (14%), gastrointestinal stromal tumor (GIST; 10%), and in salivary gland (6.1%), ovarian (5.4%), breast (4.8%), non_small cell lung (4.7%), non_melanoma skin (4.7%), and endometrial (3.7%) cancer (cBio_Zehir et al., 2017; 28481359). Published data investigating the prognostic implications of NF1 mutation in carcinomas are limited (PubMed, Jan 2022). NF1 loss was significantly associated with decreased overall and disease_specific survival in patients with grade II and III gliomas, but not in those with GBM (Vizcaino et al., 2015; 26190195). One study reported increased risk of death and poor overall survival in the NF1_mutated melanoma (Cirenajwis et al., 2017; 28267273). Another study demonstrated that NF1 is an independent prognostic factor of survival in gastric carcinoma in univariate and multivariate analysis, with no or low NF1 expression significantly associated with shorter OS (P<0.001)(Liu et al., 2017; 29137312). On the basis of clinical evidence in neurofibromatosis Type 1_associated neurofibroma (Dombi et al., 2016; 28029918, Schalkwijk et al., 2021; 33903938, Glassberg et al., 2020; ASPHO Abstract 2015, Coyne et al., 2020; ASCO Abstract 3612, McCowage et al., 2018; ASCO Abstract 10504, Mueller et al., 2020; SNO Abstract NFB_17, Toledano et al., 2021; 33751171, Waldner et al., 2020; DOI: 10.1055/s_0040_1715638, Ronsley et al., 2021; 33939292), glioma or glioblastoma (Fangusaro et al., 2019; 31151904, Manoharan et al., 2020; 32780261, Kondyli et al., 2018; 30097824, Ronsley et al., 2021; 33939292, Romo et al., 2019; SNO Abstract RARE_54, Awada et al., 2020; 33082744), and non_small cell lung cancer (Middleton et al., 2020; 32669708), NF1 inactivation may predict sensitivity to MEK inhibitors such as cobimetinib, trametinib, binimetinib, and selumetinib. On the basis of limited clinical data (Lim et al., 2016; 26859683 , Weiss et al., 2015; 25314964, Janku et al., 2014; 24931142) and preclinical data (Johannessen et al., 2008; 18164202, Johannessen et al., 2005; 15937108), loss or inactivation of NF1 may predict sensitivity to mTOR inhibitors, including everolimus and temsirolimus. A preclinical study suggests that combined mTOR and MEK inhibition is effective in a model of NF1_deficient malignant peripheral nerve sheath tumors (MPNST) (Malone et al., 2014; 24913553). One or more of the NF1 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with neurofibromatosis type 1 (ClinVar, Sep 2022)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in NF1 cause the autosomal dominant disorder neurofibromatosis type 1, which is characterized in part by increased risk of developing various tumors, including sarcoma, glioma, breast carcinoma, and neuroendocrine and hematological neoplasms (Jett and Friedman, 2010; 20027112, Patil and Chamberlain, 2012; 22240541, Evans et al., 2012; 23036231). Estimates for the prevalence of the disorder in the general population range from 1:2,500 to 1:3,000 (Upadhyaya et al., 1995; 8544190, Williams et al., 2009; 19117870), and in the appropriate clinical context, germline testing of NF1 is recommended.", "Include": "true", "ClinicalTrialNote": "On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.", "Therapies": {"Therapy": [{"Name": null, "GenericName": "Selumetinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Selumetinib is a MEK inhibitor that is FDA approved to treat pediatric patients with neurofibromatosis type 1 (NF1)_associated plexiform neurofibromas (PNs). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical evidence in neurofibromatosis type 1 (NF1)_associated neurofibroma (Dombi et al., 2016; 28029918, Schalkwijk et al., 2021; 33903938, Glassberg et al., 2020; ASPHO Abstract 2015, Coyne et al., 2020; ASCO Abstract 3612, McCowage et al., 2018; ASCO Abstract 10504, Mueller et al., 2020; SNO Abstract NFB_17, Toledano et al., 2021; 33751171, Waldner et al., 2020; DOI: 10.1055/s_0040_1715638, Ronsley et al., 2021; 33939292), glioma (Fangusaro et al., 2019; 31151904, Manoharan et al., 2020; 32780261, Kondyli et al., 2018; 30097824, Ronsley et al., 2021; 33939292, Romo et al., 2019; SNO Abstract RARE_54, Awada et al., 2020; 33082744), and non_small cell lung cancer (Middleton et al., 2020; 32669708), NF1 inactivation may predict sensitivity to MEK inhibitors. </p> <p><b>Supporting Data:</b> Selumetinib has demonstrated efficacy in NF1_associated neurofibroma in Phase 2 studies (Schalkwijk et al., 2021; 33903938, Glassberg et al., 2020; ASPHO Abstract 2015, Coyne et al., 2020; ASCO Abstract 3612) and a Phase 1 study (Dombi et al., 2016; 28029918). Phase 2 studies reported clinical responses in low_grade glioma (Fangusaro et al., 2019; 31151904, Banerjee et al., 2017; 28339824), melanoma (Gupta et al., 2014; 24567366, Robert et al., 2013; 23735514, Kirkwood et al., 2012; 22048237, Banerji et al., 2010; 20179232, Boers_Sonderen et al., 2012; 22293660), and in lung (Lopez_Chavez et al., 2015; 25667274, Hainsworth et al., 2010; 20802351, Middleton et al., 2020; 32669708) and endometrial cancer (Coleman et al., 2015; 25887099). A Phase 2 study of selumetinib for patients with activating alterations in the MAPK pathway reported a DCR of 15% (3/20), with no objective responses observed (Eckstein et al., 2022; 35363510). Phase 1 studies of selumetinib to treat patients with solid tumors reported 1/15 PR for a patient with colorectal cancer (CRC) and 5/15 SDs for patients with tonsil squamous cell carcinoma (SCC), non_small cell lung cancer (NSCLC), and CRC (Deming et al., 2016; 26666244); 2/39 PRs (for patients with CRC) and 18/39 SDs were achieved when selumetinib was administered in combination with cyclosporin A (Krishnamurthy et al., 2018; 30042150). Multiple Phase 1 studies combining selumetinib with erlotinib or temsirolimus (Infante et al., 2017; 28424891), docetaxel or dacarbazine (LoRusso et al., 2017; 28264648), AKT inhibitors (Tolcher et al., 2015; 25516890), or cixutumumab (an anti_IGF_1R antibody)(Wilky et al., 2015; 25268371) reported clinical responses for patients with advanced solid tumors including NSCLC, thyroid carcinoma, tongue SCC, and ovarian cancer. </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Cobimetinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Cobimetinib is a MEK inhibitor that is FDA approved to treat patients with histiocytic neoplasms. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical evidence in neurofibromatosis type 1 (NF1)_associated neurofibroma (Dombi et al., 2016; 28029918, Schalkwijk et al., 2021; 33903938, Glassberg et al., 2020; ASPHO Abstract 2015, Coyne et al., 2020; ASCO Abstract 3612, McCowage et al., 2018; ASCO Abstract 10504, Mueller et al., 2020; SNO Abstract NFB_17, Toledano et al., 2021; 33751171, Waldner et al., 2020; DOI: 10.1055/s_0040_1715638, Ronsley et al., 2021; 33939292), glioma (Fangusaro et al., 2019; 31151904, Manoharan et al., 2020; 32780261, Kondyli et al., 2018; 30097824, Ronsley et al., 2021; 33939292, Romo et al., 2019; SNO Abstract RARE_54, Awada et al., 2020; 33082744), and non_small cell lung cancer (Middleton et al., 2020; 32669708), NF1 inactivation may predict sensitivity to MEK inhibitors. </p> <p><b>Supporting Data:</b> Single_agent cobimetinib has shown clinical activity in the context of histiocytic neoplasms, including Langerhans cell histiocytosis, Erdheim_Chester disease, Rosai_Dorfman disease, nodular histiocytosis, and mixed histiocytosis (Diamond et al., 2015; 26566875, Diamond et al., 2019; 30867592, Jacobsen et al., 2019; 29236635, Berce et al., 2022; 35372654, Giuffre et al., 2020; 32823478, Razanamahery et al., 2020; 31376269, Moyon et al., 2020; 31669429, Gupta et al., 2022; 36135991). A Phase 1 study of cobimetinib monotherapy in solid tumors reported CRs for 1.0% (1/97) of patients and PRs for 6.2% (6/97) of patients, all of whom had melanoma (Rosen et al., 2016; 27424159). Clinical benefit following treatment with cobimetinib has been seen for patients with non_small cell lung cancer (NSCLC) (Cho et al., 2020; AACR Abstract CT201, Rosen et al., 2016; 27424159), adenoid cystic carcinoma (Rosen et al., 2016; 27424159), and anaplastic pleomorphic xanthoastrocytoma (Touat et al., 2019; DOI: 10.1200/PO.18.00298). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Trametinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Trametinib is a MEK inhibitor that is FDA approved as a monotherapy to treat patients with melanoma with BRAF V600E or V600K mutations. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical evidence in neurofibromatosis type 1 (NF1)_associated neurofibroma (Dombi et al., 2016; 28029918, Schalkwijk et al., 2021; 33903938, Glassberg et al., 2020; ASPHO Abstract 2015, Coyne et al., 2020; ASCO Abstract 3612, McCowage et al., 2018; ASCO Abstract 10504, Mueller et al., 2020; SNO Abstract NFB_17, Toledano et al., 2021; 33751171, Waldner et al., 2020; DOI: 10.1055/s_0040_1715638, Ronsley et al., 2021; 33939292), glioma (Fangusaro et al., 2019; 31151904, Manoharan et al., 2020; 32780261, Kondyli et al., 2018; 30097824, Ronsley et al., 2021; 33939292, Romo et al., 2019; SNO Abstract RARE_54, Awada et al., 2020; 33082744), and non_small cell lung cancer (Middleton et al., 2020; 32669708), NF1 inactivation may predict sensitivity to MEK inhibitors. </p> <p><b>Supporting Data:</b> A Phase 1 trial of trametinib in 206 patients with solid tumors reported 21 (10%) objective responses (Infante et al., 2012; 22805291). Phase 1 monotherapy trials of RO4987655, another MEK inhibitor, have shown significant response rates in patients with melanoma, including those with BRAF and NRAS mutations, but very low response rates in patients with other solid tumors, including those with KRAS mutations (Leijen et al., 2012; 22767668, Zimmer et al., 2014; 24947927). A Phase 1b trial of trametinib in combination with gemcitabine in patients with solid tumors showed a complete response in a patient with breast cancer, as well as partial responses in pancreatic and salivary gland cancer (Infante et al., 2013; 23583440). A Phase 1b trial of combination treatment with the MEK inhibitor binimetinib and the PI3K_alpha inhibitor alpelisib reported disease control (partial responses or stable disease) in 47% (21/45) of patients, including partial responses in 2 of 3 patients with KRAS_mutant ovarian cancer and 1 of 3 patients with NRAS_mutant melanoma; a 43% rate of stable disease was observed in patients with KRAS_mutant colorectal cancer, with responses independent of PIK3CA mutation status (Juric et al., 2014; ASCO Abstract 9051). Whereas frequent adverse events precluded a recommended Phase 2 dose and schedule for the combination of trametinib and everolimus in a Phase 1b trial for solid tumors (Tolcher et al., 2014; 25344362), a retrospective study for heavily pretreated patients with solid tumors reported tolerable regimens of the combination for 23/31 patients, with 16 patients treated >3 months and evaluable patients achieving a median PFS of 6.5 months (Patterson et al., 2018; AACR Abstract 3891). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}]}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT03239015", "Include": "true"}, {"nctId": "NCT04337463", "Include": "true"}, {"nctId": "NCT04985604", "Include": "true"}, {"nctId": "NCT04803318", "Include": "true"}, {"nctId": "NCT05125523", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT03498521", "Include": "true"}, {"nctId": "NCT03297606", "Include": "true"}, {"nctId": "NCT04720976", "Include": "true"}, {"nctId": "NCT04965818", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "Blood Tumor Mutational Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "04", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "04"}}, "Interpretation": "Blood tumor mutational burden (bTMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations from circulating tumor DNA in blood. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). High bTMB levels were not detected in this sample. It is unclear whether the bTMB levels in this sample would be predicted to be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors, alone or in combination with other agents (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Aggarwal et al., 2020; 32102950, Rizvi et al., 2019; ASCO Abstract 9016). Depending on the clinical context, TMB testing of an alternate sample or by another methodology could be considered. Average bTMB levels in solid tumors other than NSCLC have not been evaluated (PubMed, Mar 2022). Published data investigating the prognostic implications of TMB have mainly been investigated in the context of tissue TMB. In patients with NSCLC, increased TMB is associated with higher tumor grade and poor prognosis (Xiao et al., 2016; 27009843), as well as with a decreased frequency of known driver mutations in EGFR, ALK, ROS1, or MET (1% of high_TMB samples each), but not BRAF (10.3%) or KRAS (9.4%) (Spigel et al., 2016; ASCO Abstract 9017). Although some studies have reported a lack of association between smoking and increased TMB in NSCLC (Schwartz et al., 2016; ASCO Abstract 8533, Xiao et al., 2016; 27009843, Shim et al., 2015; 26200269), several other large studies did find a strong link (Govindan et al., 2012; 22980976, Ding et al., 2008; 18948947, Imielinski et al., 2012; 22980975, Kim et al., 2014; 24323028). In CRC, elevated TMB is associated with a higher frequency of BRAF V600E driver mutations (Cancer Genome Atlas Network, 2012; 22810696, Stadler et al., 2016; 27022117) and with microsatellite instability (MSI) (George et al., 2016; ASCO Abstract 3587, Nagahashi et al., 2016; ASCO Abstract e15103, Stadler et al., 2016; 27022117), which in turn has been reported to correlate with better prognosis (Samowitz et al., 2001; 11535541, Elsaleh and Iacopetta, 2001; 12445368, Brueckl et al., 2003; 12820457, Guidoboni et al., 2001; 11438476, Gryfe et al., 2000; 10631274, Sinicrope et al., 2006; 16952542, Guastadisegni et al., 2010; 20627535, Laghi and Malesci, 2012; 22722556). Although increased TMB is associated with increased tumor grade in endometrioid endometrial carcinoma (Mehnert et al., 2016; 27159395, Cancer Genome Atlas Research Network., 2013; 23636398, Hussein et al., 2015; 25394778, Church et al., 2013; 23528559) and bladder cancer (Cazier et al., 2016; 24777035), it is also linked with improved prognosis in patients with these tumor types (Rosenberg et al., 2016; ASCO Abstract 104, Cancer Genome Atlas Research Network., 2013; 23636398). On the basis of clinical evidence in solid tumors, increased blood tumor mutational burden (bTMB) may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Li et al., 2020; ASCO Abstract 6511, Saori et al., 2021; ESMO Abstract 80P, Sturgill et al., 2022; 35274716), anti_PD_1 (Schenker et al., 2022; AACR Abstract CT022, Aggarwal et al., 2020; 32102950, Peters et al., 2019; AACR Abstract CT074, Saori et al., 2021; ESMO Abstract 80P, Sturgill et al., 2022; 35274716), anti_PD_1/CTLA4 therapies (Schenker et al., 2022; AACR Abstract CT022, Saori et al., 2021; ESMO Abstract 80P), anti_PD_L1/CTLA4 therapies (Chen et al., 2020; 32379280, Loree et al., 2021; ASCO GI Abstract 61, Li et al., 2020; ASCO Abstract 6511, Rizvi et al., 2020; 32271377, Si et al., 2021; 33355200, Leighl et al., 2022; 34800700). A Phase 2 multi_solid_tumor trial showed that bTMB \u226516 Muts/Mb (as measured by this assay) was associated with improved survival from treatment with a PD_1 inhibitor alone or in combination with a CTLA_4 inhibitor (Schenker et al., 2022; AACR Abstract CT022). In non_small cell lung cancer (NSCLC), multiple clinical trials have shown patients with higher bTMB derive clinical benefit from immune checkpoint inhibitors following single_agent or combination treatments with either CTLA4 inhibitors or chemotherapy, with reported high bTMB cutpoints ranging from 6 Muts/Mb_16 Muts/Mb (Gandara et al., 2018; 30082870, Socinski et al., 2019 ESMO Abstract LBA83, Aggarwal et al. 2020; 32102950, Rizvi et al., 2020; 32271377, Si et al., 2021; 33355200, Leighl et al., 2022; 34800700). In head and neck squamous cell carcinoma (HNSCC), a Phase 3 trial showed that bTMB \u226516 Muts/Mb (approximate equivalency \u22658 Muts/Mb as measured by this assay) was associated with improved survival from treatment with a PD_L1 inhibitor alone or in combination with a CTLA_4 inhibitor (Li et al., 2020; ASCO Abstract 6511). In colorectal cancer (CRC), a Phase 2 study showed that bTMB TMB \u226528 Muts/Mb (approximate equivalency \u226514 Muts/Mb as measured by this assay) was associated with improved OS from a PD_L1 inhibitor alone or in combination with a CTLA_4 inhibitor (Loree et al., 2021; ASCO GI Abstract 61, Chen et al., 2020; 32379280).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "GNAS", "Include": "true", "Alterations": {"Alteration": {"Name": "R201H", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "0.25", "isEquivocal": "false", "name": "R201H"}}, "Interpretation": "GNAS encodes the alpha subunit of the stimulatory G protein (Gs_alpha) (Hayward et al., 1998; 9860993). Gs_alpha is a guanine_nucleotide binding protein (G protein) that is involved in hormonal regulation of adenylate cyclase (Hayward et al., 1998; 9860993). GNAS has been reported to be amplified in cancer (Gao et al., 2013; 23550210) and may be biologically relevant in this context (Zack et al., 2013; 24071852, Beroukhim et al., 2010; 20164920). GNAS alterations that have been shown to result in constitutive activation of adenylyl cyclase and an increase in cellular cAMP concentration (Masters et al., 1989; 2549064, Graziano and Gilman, 1989; 2549065, Jang and Juhnn, 2001; 11322485, Landis et al., 1989; 2549426, Tobar_Rubin et al., 2013; 23288949, Mariot et al., 2011; 20887824) are predicted to be activating. Mutations at R201 specifically are commonly associated with McCune_Albright syndrome, a disease that can co_occur with various cancers in patients with GNAS activating mutations (Weinstein et al., 1991; 1944469, Collins et al., 2003; 12970318, Nault et al., 2012; 21835143). The highest incidences of GNAS mutations have been reported in intraductal papillary mucinous neoplasms (40_66%)(Furukawa et al., 2011; 22355676, Wu et al., 2011; 21775669) and appendiceal mucinous neoplasms (50_72%)(Nishikawa et al., 2013; 23403822, Singhi et al., 2014; 24925222) as well as in tumors affecting the peritoneum (22%), pituitary gland (20%), bone (14%), pancreas (11%), and small intestine (11%)(COSMIC, 2022)(Tate et al., 2019; 30371878). Amplification of GNAS has been reported in ovarian epithelial carcinomas (12_30%)(Cancer Genome Atlas Research Network., 2011; 21720365, Kan et al., 2010; 20668451, Tominaga et al., 2010; 20537689), colorectal adenocarcinoma (9%)(Cancer Genome Atlas Network., 2012; 22810696), stomach adenocarcinoma (7%)(Cancer Genome Atlas Research Network., 2014; 25079317), lung adenocarcinoma (6.5%)(Cancer Genome Atlas Research Network., 2014; 25079552), breast invasive carcinoma (6.5%)(Cancer Genome Atlas Network., 2012; 23000897), pancreatic adenocarcinoma (6%)(Bio_Witkiewicz et al., 2015; 25855536), and sarcomas (5.8%)(cBio_Barretina et al., 2010; 20601955). GNAS mutations are rare in hematological malignancies generally (COSMIC, 2022)(Tate et al., 2019; 30371878, cBio_Lohr et al., 2014; 24434212, Chapman et al., 2011; 21430775). Activating GNAS mutations have been identified in gastrointestinal polyps in 75% (3/4) of patients with McCune_Albright syndrome (Zacharin et al., 2011; 21357941). Amplification of GNAS has been associated with shorter progression_free survival in patients with ovarian cancer (Kan et al., 2010; 20668451, Tominaga et al., 2010; 20537689), while activating GNAS mutations have been correlated with tumor progression and poor prognosis in patients with gastric cancer (Alakus et al., 2009; 20027678). There are no therapies targeted to GNAS mutation in cancer. However, there is limited data indicating that a patient with appendiceal adenocarcinoma and a GNAS mutation (R201H) benefited from trametinib for 4 months (Ang et al., 2017; 28868010). Additionally, a patient with GNAS_mutated Erdheim_Chester disease exhibited a PR following treatment with single_agent trametinib (Saunders et al., 2019; 31740567).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "Cannot Be Determined", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Cannot Be Determined"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). The level of MSI in this sample could not be determined with confidence. Depending on the clinical context, MSI testing of an alternate sample or by another methodology could be considered. MSI_high (MSI_H) has been observed at high frequency in endometrial cancers (14_33%)(Santin et al., ASCO 2016; Abstract 414, Zighelboim et al., 2007; 17513808, Hampel et al., 2006; 16885385, Stelloo et al., 2016; 27006490, Kanopiene et al., 2014; 25458958, Black et al., 2006; 16549821, Nout et al., 2012; 22609107, Steinbakk et al., 2011; 21547578, Bilbao et al., 2010; 20005452), colorectal cancers (CRCs; 10_15%)(Guastadisegni et al., 2010; 20627535, Pawlik et al., 2004; 15528785, Kocarnik et al., 2015; 26337942, Cancer Genome Atlas Network., 2012; 22810696, Lal et al., 2015; 25949894), and gastric cancers (12_35%)(Hiyama et al., 2004; 15209621, Wu et al., 1998; 9537253, dos Santos et al., 1996; 8536886, Fang et al., 2013; 23555086) and at lower frequencies in many other tumor types, including esophageal (Hall et al., 2016; ASCO Gastrointestinal Cancer Symposium Abstract 528, Farris et al., 2011; 21422910), small bowel (Gingras et al., 2015; AACR Pancreatic Cancer Abstract PR06, Agaramet al., 2010; 20395525, Ruemmele et al., 2009; 19252434, Planck et al., 2003; 12627520, Hibi et al., 1995; 7775257, Muneyuki et al., 2000; 11117578), hepatobiliary (Zhang et al., 2005; 15918185, Chiappini et al., 2004; 14656944, Suto et al., 2001; 11223838, Momoi et al., 2001; 11580146, Liengswangwong et al., 2003; 14506736, Moy et al., 2015; 25680569, Yoshida et al., 2000; 11063221), prostate (Cheng et al., 2016; Genitourinary Cancers Symposium Abstract 251, Pritchard et al., 2014; 25255306, Azzouzi et al., 2007; 17233803, Burger et al., 2006; 16924473), and urinary tract carcinomas (Harper et al., 2015; USCAP Abstract 905, Bai et al., 2013; 23690119, Giedl et al., 2014; 25319978, Yamamoto et al., 2006; 16675567). In one study, MSI_H status was associated with a positive prognostic effect in patients with gastric cancer treated with surgery alone and a negative predictive effect in patients treated with chemotherapy (Smyth et al., 2015; ASCO Gastrointestinal Cancers Symposium Abstract 62). Data regarding the role of MSI_H on prognosis and survival in endometrial cancer are conflicting (Zighelboim et al., 2007; 17513808, Kanopiene et al., 2014; 25458958, Bilbao_Sieyro et al., 2014; 25026289, Mackay et al., 2010; 20304627, Steinbakk et al., 2011; 21547578, Arabi et al., 2009; 19275958, Black et al., 2006; 16549821). However, studies specifically analyzing early stage endometrial cancer have reported a correlation between MSI_H and decreased survival (Stelloo et al., 2016; 27006490, Mackay et al., 2010; 20304627, Nout et al., 2012; 22609107, Bilbao et al., 2010; 20005452), thereby suggesting that MSI_H predicts for poor prognosis in this subset of endometrial tumors. On the basis of prospective clinical evidence in multiple solid tumor types, microsatellite instability (MSI) and associated increased tumor mutational burden (TMB) (Jass, 2007; 17204026, Lal et al., 2015; 25949894) may predict sensitivity to immune checkpoint inhibitors, including the approved PD_1_targeting agents cemiplimab, dostarlimab, nivolumab (alone or in combination with ipilimumab), and pembrolizumab (Overman et al., 2017; 28734759, Overman et al., 2018; 29355075, Overman et al., 2019; ASCO Abstract 635, Shitara et al., 2022; 35322232, Andre et al., 2022; ASCO GI Abstract 244, Lipson et al., 2013; 23169436, Le et al., 2015; 26028255, Rizvi et al., 2015; 25765070, Oaknin et al., 2020; 33001143), as well as PD_L1_targeting agents atezolizumab, avelumab, and durvalumab (Hochster et al., 2017; ASCO Abstract 673, Fleming et al., 2018; ASCO Abstract 5585, Bang et al., 2018; ASCO Abstract 92). As the MSI status of this tumor is unknown, the relevance of these therapeutic approaches is unclear.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "TP53", "Include": "true", "Alterations": {"Alteration": {"Name": "G245S", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "0.55", "isEquivocal": "false", "name": "G245S"}}, "Interpretation": "Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers (Brown et al., 2009; 19935675). Alterations such as seen here may disrupt TP53 function or expression (Joerger and Fersht, 2008; 18410249, Kato et al., 2003; 12826609, Kamada et al., 2011; 20978130, Zerdoumi et al., 2017; 28472496, Yamada et al., 2007; 17690113). Pan_cancer analysis of the TCGA datasets across 12 cancer types identified TP53 as the most frequently mutated gene, with 42% of more than 3,000 tumors harboring a TP53 mutation; in this study TP53 mutation occurred most frequently in ovarian serous carcinoma (95%), lung squamous cell carcinoma (SCC) (79%), head and neck SCC (70%), colorectal adenocarcinoma (59%), lung adenocarcinoma (52%), and bladder urothelial carcinoma (50%) (Kandoth et al., 2013; 24132290). TP53 loss of heterozygosity (LOH) is frequently seen in tumors and often occurs when one copy of TP53 harbors a mutation; in some tumors, LOH is correlated with progression (Wongsurawat et al., 2006; 16537709, Brosh and Rotter, 2009; 19693097, Baker et al., 1989; 2649981, Calcagno et al., 2013; 24053468). While the prognostic significance of TP53 alteration or dysregulation varies according to tumor type, studies have shown an association with poor prognosis for patients with breast cancer (Alsner et al., 2008; 18465328, Olivier et al., 2006; 16489069, V\u00e9gran et al., 2013; 23359294), endometrial cancer (Wild et al., 2012; 22678923, Lee et al., 2010; 20006376), HNSCC (Ganci et al., 2013; 24107801, Lindenbergh_van et al., 2011; 21467160, Peltonen et al., 2011; 21513535), or urothelial cancer (Bringuier et al., 1998; 9761125, Feng et al., 2014; 24500328). In one study of 55 patients with lung adenocarcinoma, TP53 alterations correlated with immunogenic features including PD_L1 expression, tumor mutation burden and neoantigen presentation; likely as a consequence of this association TP53 mutations correlated with improved clinical outcomes to PD_1 inhibitors pembrolizumab and nivolumab in this study (Dong et al., 2016; 28039262). TP53 mutation has not been consistently demonstrated to be a significant independent prognostic marker in the context of CRC (Russo et al., 2005; 16172461, Fong et al., 2022; ASCO GI Abstract 57). There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib (Hirai et al., 2010; 20107315, Bridges et al., 2011; 21799033, Rajeshkumar et al., 2011; 21389100, Osman et al., 2015; 25504633) or p53 gene therapy such as SGT53 (Xu et al., 2002; 12489850, Xu et al., 2001; 11713371, Camp et al., 2013; 23470564, Kim et al., 2015; 25240597, Pirollo et al., 2016; 27357628, Leung et al., 2021; ASCO Abstract 4139). In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype (Leijen et al., 2016; 27601554). A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 32% (30/94, 3 CR) ORR and a 73% (69/94) DCR for patients with platinum_refractory TP53_mutated ovarian, Fallopian tube, or peritoneal cancer (Moore et al., 2019; ASCO Abstract 5513). A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR for patients with platinum_refractory TP53_mutated ovarian cancer (Leijen et al., 2016; 27998224). The combination of adavosertib with paclitaxel and carboplatin for patients with TP53_mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone (Oza et al., 2015; ASCO Abstract 5506). In the Phase 2 VIKTORY trial, patients with TP53_mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib combined with paclitaxel (Lee et al., 2019; 31315834). A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations (Mendez et al., 2018; 29535125). The Phase 2 FOCUS4_C trial for patients with TP53_ and RAS_mutated colorectal cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring (Seligmann et al., 2021; 34538072). In a Phase 1b clinical trial of SGT_53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage (Pirollo et al., 2016; 27357628). Missense mutations leading to TP53 inactivation may be sensitive to therapies that reactivate mutated p53 such as eprenetapopt. In a Phase 1b trial for patients with p53_positive high_grade serous ovarian cancer, eprenetapopt combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR (Gourley et al., 2016; ASCO Abstract 5571). A Phase 1 trial of eprenetapopt with pembrolizumab for patients with solid tumors reported an ORR of 10% (3/29) (Park et al., 2022; 36084396). One or more of the TP53 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with Li_Fraumeni syndrome (ClinVar, Sep 2022)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li_Fraumeni syndrome and the early onset of many cancers (Bougeard et al., 2015; 26014290, Sorrell et al., 2013; 23355100, Nichols et al., 2001; 11219776), including sarcomas (Kleihues et al., 1997; 9006316, Gonzalez et al., 2009; 19204208). Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000 (Lalloo et al., 2003; 12672316) to 1:20,000 (Gonzalez et al., 2009; 19204208). For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30 (Mandelker et al., 2019; 31050713). In the appropriate clinical context, germline testing of TP53 is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Fraction", "Include": "true", "Alterations": {"Alteration": {"Name": "Elevated Tumor Fraction Not Detected", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Elevated Tumor Fraction Not Detected"}}, "Interpretation": "Tumor fraction provides an estimate of the percentage of ctDNA present in a cell_free DNA (cfDNA) sample. The tumor fraction estimate for this sample is based on the observed level of aneuploid instability. The tumor fraction algorithm utilized for FoundationOne Liquid CDx uses the allele frequencies of approximately 1,000 single_nucleotide polymorphism (SNP) sites across the genome. Unlike the maximum somatic allele frequency (MSAF) method of estimating ctDNA content (Li et al., 2019; 31602320), the tumor fraction metric does not take into account the allele frequency of individual variants but rather produces a more holistic estimate of ctDNA content using data from across the genome. The amount of ctDNA detected may correlate with disease burden and response to therapy (Zhang et al., 2020; 32757294, Butler et al., 2019; 30833418). Detectible ctDNA levels have been reported in a variety of tumor types, with higher tumor fraction levels reported for patients with metastatic (Stage 4) tumors compared with patients with localized disease (Stages 1 to 3) (Bettegowda et al., 2014; 24553385). Elevated tumor fraction levels have been reported to be associated with worse prognosis in a variety of cancer types, including pancreatic cancer (Lapin et al., 2018; 30400802), Ewing sarcoma and osteosarcoma (Shulman et al., 2018; 30131550), prostate cancer (Choudhury et al., 2018; 30385733, Conteduca et al., 2019; ASCO abstract 5039), breast cancer (Stover et al., 2018; 29298117), leiomyosarcoma (Hemming et al., 2019; 30793095), esophageal cancer (Egyud et al., 2019; 31059681), colorectal cancer (Fan et al., 2017; 28187169), and gastrointestinal cancer (Vu et al., 2020; DOI: 10.1200/PO.19.00204). Specimens with elevated tumor fraction values have high circulating_tumor DNA (ctDNA) content, and thus high sensitivity for identifying genomic alterations. Such specimens are at low risk of false negative results. However, if elevated tumor fraction is not detected, it does not exclude the presence of disease burden or compromise the confidence of reported alterations. Tumor fraction levels currently have limited implications for diagnosis, surveillance, or therapy and should not be overinterpreted or compared from one blood draw to another. There are currently no targeted approaches to address specific tumor fraction levels. In the research setting, changes in tumor fraction estimates have been associated with treatment duration and clinical response and may be a useful indicator for future cancer management (Bronkhorst et al., 2019; 30923679, Raja et al., 2018; 30093454, Hrebien et al., 2019; 30860573, Conteduca et al., 2019; ASCO Abstract 5039, Choudhury et al., 2018; 30385733, Goodall et al., 2017; 28450425, Goldberg et al., 2018; 29330207).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "NF1", "Alteration": "I679fs*21", "Title": "Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event", "StudyPhase": "PHASE 2", "Target": "EGFR, ERBB4, ERBB2, PARP, mTOR, MET, ROS1, RET, VEGFRs, BRAF, CDK4, CDK6", "Locations": "Shanghai (China)", "NCTID": "NCT03239015", "Note": "On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "NF1", "Alteration": "I679fs*21", "Title": "ATG_008 Combined With Toripalimab in Advanced Solid Tumors", "StudyPhase": "PHASE null", "Target": "mTORC1, mTORC2, PD_1", "Locations": "Chongqing (China), Chengdu (China)", "NCTID": "NCT04337463", "Note": "On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "NF1", "Alteration": "I679fs*21", "Title": "DAY101 Monotherapy or in Combination With Other Therapies for Patients With Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "BRAF, MEK", "Locations": "Busan (Korea, Republic of), Seoul (Korea, Republic of), Oregon, Barcelona (Spain), Madrid (Spain), California, Colorado, Toronto (Canada), Indiana", "NCTID": "NCT04985604", "Note": "On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "NF1", "Alteration": "I679fs*21", "Title": "Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors", "StudyPhase": "PHASE 2", "Target": "mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK", "Locations": "Guangzhou (China)", "NCTID": "NCT04803318", "Note": "On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "NF1", "Alteration": "I679fs*21", "Title": "A Study of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid Tumors", "StudyPhase": "PHASE 1", "Target": "mTOR", "Locations": "Tianjin (China)", "NCTID": "NCT05125523", "Note": "On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "NF1", "Alteration": "I679fs*21", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "NF1", "Alteration": "I679fs*21", "Title": "A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum_Based Chemotherapy in Patients With Cancer of Unknown Primary Site", "StudyPhase": "PHASE 2", "Target": "ALK, RET, SMO, AKTs, PARP, PD_L1, EGFR, VEGFA, MEK, BRAF, ERBB2, TRKB, TRKC, ROS1, TRKA", "Locations": "Kecskemet (Hungary), Monterrey (Mexico), Cdmx (Mexico), Temuco (Chile), Recoleta (Chile)", "NCTID": "NCT03498521", "Note": "On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "NF1", "Alteration": "I679fs*21", "Title": "Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)", "StudyPhase": "PHASE 2", "Target": "VEGFRs, ABL, SRC, ALK, ROS1, AXL, TRKA, MET, TRKC, DDR2, KIT, EGFR, PD_1, CTLA_4, PARP, CDK4, CDK6, FLT3, CSF1R, RET, mTOR, ERBB2, MEK, BRAF, SMO", "Locations": "Vancouver (Canada), Edmonton (Canada), Saskatoon (Canada), Regina (Canada), Ottawa (Canada), Montreal (Canada), Toronto (Canada), Kingston (Canada), London (Canada)", "NCTID": "NCT03297606", "Note": "On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "NF1", "Alteration": "I679fs*21", "Title": "JAB_3312 Activity in Adult Patients With Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "MEK, SHP2, PD_1, EGFR, KRAS", "Locations": "Utah, California, Arizona, Minnesota, Illinois, Michigan, Oklahoma, Missouri, Indiana, Connecticut", "NCTID": "NCT04720976", "Note": "On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "NF1", "Alteration": "I679fs*21", "Title": "Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer", "StudyPhase": "PHASE 1/2", "Target": "MEK, FGFRs", "Locations": "California, Indiana, Texas", "NCTID": "NCT04965818", "Note": "On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "1904223", "FullCitation": "Hattori S, et al. Biochem. Biophys. Res. Commun. (1991) pmid: 1904223", "Include": "true"}, {"number": "1", "ReferenceId": "8628317", "FullCitation": "Morcos P, et al. Mol. Cell. Biol. (1996) pmid: 8628317", "Include": "true"}, {"number": "2", "ReferenceId": "2121371", "FullCitation": "Ballester R, et al. Cell (1990) pmid: 2121371", "Include": "true"}, {"number": "3", "ReferenceId": "2116237", "FullCitation": "Xu GF, et al. Cell (1990) pmid: 2116237", "Include": "true"}, {"number": "4", "ReferenceId": "2121370", "FullCitation": "Martin GA, et al. Cell (1990) pmid: 2121370", "Include": "true"}, {"number": "5", "ReferenceId": "22807134", "FullCitation": "Thomas L, et al. Hum. Mutat. (2012) pmid: 22807134", "Include": "true"}, {"number": "6", "ReferenceId": "9300663", "FullCitation": "Skuse GR, et al. Hum. Mol. Genet. (1997) pmid: 9300663", "Include": "true"}, {"number": "7", "ReferenceId": "11258625", "FullCitation": "Messiaen LM, et al. Genet. Med. () pmid: 11258625", "Include": "true"}, {"number": "8", "ReferenceId": "10607834", "FullCitation": "Ars E, et al. Hum. Mol. Genet. (2000) pmid: 10607834", "Include": "true"}, {"number": "9", "ReferenceId": "15863657", "FullCitation": "Messiaen LM, et al. J. Med. Genet. (2005) pmid: 15863657", "Include": "true"}, {"number": "10", "ReferenceId": "8264648", "FullCitation": "Poullet P, et al. Mol. Cell. Biol. (1994) pmid: 8264648", "Include": "true"}, {"number": "11", "ReferenceId": "28481359", "FullCitation": "Zehir A, et al. Nat. Med. (2017) pmid: 28481359", "Include": "true"}, {"number": "12", "ReferenceId": "26190195", "FullCitation": "Vizca\u00edno MA, et al. Hum. Pathol. (2015) pmid: 26190195", "Include": "true"}, {"number": "13", "ReferenceId": "28267273", "FullCitation": "Cirenajwis H, et al. Mol Oncol (2017) pmid: 28267273", "Include": "true"}, {"number": "14", "ReferenceId": "29137312", "FullCitation": "Liu D, et al. Oncotarget (2017) pmid: 29137312", "Include": "true"}, {"number": "15", "ReferenceId": "28029918", "FullCitation": "Dombi E, et al. N. Engl. J. Med. (2016) pmid: 28029918", "Include": "true"}, {"number": "16", "ReferenceId": "33903938", "FullCitation": "Schalkwijk S, et al. Cancer Chemother Pharmacol (2021) pmid: 33903938", "Include": "true"}, {"number": "17", "ReferenceId": "33751171", "FullCitation": "Toledano H, et al. Childs Nerv Syst (2021) pmid: 33751171", "Include": "true"}, {"number": "18", "ReferenceId": "33939292", "FullCitation": "Ronsley R, et al. Cancer Med (2021) pmid: 33939292", "Include": "true"}, {"number": "19", "ReferenceId": "31151904", "FullCitation": "Fangusaro J, et al. Lancet Oncol. (2019) pmid: 31151904", "Include": "true"}, {"number": "20", "ReferenceId": "32780261", "FullCitation": "Manoharan N, et al. J Neurooncol (2020) pmid: 32780261", "Include": "true"}, {"number": "21", "ReferenceId": "30097824", "FullCitation": "Kondyli M, et al. J Neurooncol (2018) pmid: 30097824", "Include": "true"}, {"number": "22", "ReferenceId": "33082744", "FullCitation": "Awada G, et al. Case Rep Oncol () pmid: 33082744", "Include": "true"}, {"number": "23", "ReferenceId": "32669708", "FullCitation": "Middleton G, et al. Nature (2020) pmid: 32669708", "Include": "true"}, {"number": "24", "ReferenceId": "26859683", "FullCitation": "Lim SM, et al. Oncotarget (2016) pmid: 26859683", "Include": "true"}, {"number": "25", "ReferenceId": "25314964", "FullCitation": "Weiss B, et al. Neuro_oncology (2015) pmid: 25314964", "Include": "true"}, {"number": "26", "ReferenceId": "24931142", "FullCitation": "Janku F, et al. Oncotarget (2014) pmid: 24931142", "Include": "true"}, {"number": "27", "ReferenceId": "18164202", "FullCitation": "Johannessen CM, et al. Curr. Biol. (2008) pmid: 18164202", "Include": "true"}, {"number": "28", "ReferenceId": "15937108", "FullCitation": "Johannessen CM, et al. Proc. Natl. Acad. Sci. U.S.A. (2005) pmid: 15937108", "Include": "true"}, {"number": "29", "ReferenceId": "24913553", "FullCitation": "Malone CF, et al. Cancer Discov (2014) pmid: 24913553", "Include": "true"}, {"number": "30", "ReferenceId": "29165669", "FullCitation": "Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669", "Include": "true"}, {"number": "31", "ReferenceId": "20027112", "FullCitation": "Jett K, et al. Genet. Med. (2010) pmid: 20027112", "Include": "true"}, {"number": "32", "ReferenceId": "22240541", "FullCitation": "Patil S, et al. Oncologist (2012) pmid: 22240541", "Include": "true"}, {"number": "33", "ReferenceId": "23036231", "FullCitation": "Evans DG, et al. Clin Sarcoma Res (2012) pmid: 23036231", "Include": "true"}, {"number": "34", "ReferenceId": "8544190", "FullCitation": "Upadhyaya M, et al. J. Med. Genet. (1995) pmid: 8544190", "Include": "true"}, {"number": "35", "ReferenceId": "19117870", "FullCitation": "Williams VC, et al. Pediatrics (2009) pmid: 19117870", "Include": "true"}, {"number": "36", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "37", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "38", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "39", "ReferenceId": "17513808", "FullCitation": "Zighelboim I, et al. J. Clin. Oncol. (2007) pmid: 17513808", "Include": "true"}, {"number": "40", "ReferenceId": "16885385", "FullCitation": "Hampel H, et al. Cancer Res. (2006) pmid: 16885385", "Include": "true"}, {"number": "41", "ReferenceId": "27006490", "FullCitation": "Stelloo E, et al. Clin. Cancer Res. (2016) pmid: 27006490", "Include": "true"}, {"number": "42", "ReferenceId": "25458958", "FullCitation": "Kanopien\u0117 D, et al. Medicina (Kaunas) (2014) pmid: 25458958", "Include": "true"}, {"number": "43", "ReferenceId": "16549821", "FullCitation": "Black D, et al. J. Clin. Oncol. (2006) pmid: 16549821", "Include": "true"}, {"number": "44", "ReferenceId": "22609107", "FullCitation": "Nout RA, et al. Gynecol. Oncol. (2012) pmid: 22609107", "Include": "true"}, {"number": "45", "ReferenceId": "21547578", "FullCitation": "Steinbakk A, et al. Cell Oncol (Dordr) (2011) pmid: 21547578", "Include": "true"}, {"number": "46", "ReferenceId": "20005452", "FullCitation": "Bilbao C, et al. Int. J. Radiat. Oncol. Biol. Phys. (2010) pmid: 20005452", "Include": "true"}, {"number": "47", "ReferenceId": "20627535", "FullCitation": "Guastadisegni C, et al. Eur. J. Cancer (2010) pmid: 20627535", "Include": "true"}, {"number": "48", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "49", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "50", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "51", "ReferenceId": "15209621", "FullCitation": "Hiyama T, et al. J. Gastroenterol. Hepatol. (2004) pmid: 15209621", "Include": "true"}, {"number": "52", "ReferenceId": "9537253", "FullCitation": "Wu MS, et al. Cancer Res. (1998) pmid: 9537253", "Include": "true"}, {"number": "53", "ReferenceId": "8536886", "FullCitation": "dos Santos NR, et al. Gastroenterology (1996) pmid: 8536886", "Include": "true"}, {"number": "54", "ReferenceId": "23555086", "FullCitation": "Fang WL, et al. Biomed Res Int (2013) pmid: 23555086", "Include": "true"}, {"number": "55", "ReferenceId": "21422910", "FullCitation": "Farris AB, et al. Am. J. Surg. Pathol. (2011) pmid: 21422910", "Include": "true"}, {"number": "56", "ReferenceId": "20395525", "FullCitation": "Agaram NP, et al. Am. J. Clin. Pathol. (2010) pmid: 20395525", "Include": "true"}, {"number": "57", "ReferenceId": "19252434", "FullCitation": "Ruemmele P, et al. Am. J. Surg. Pathol. (2009) pmid: 19252434", "Include": "true"}, {"number": "58", "ReferenceId": "12627520", "FullCitation": "Planck M, et al. Cancer (2003) pmid: 12627520", "Include": "true"}, {"number": "59", "ReferenceId": "7775257", "FullCitation": "Hibi K, et al. Jpn. J. Cancer Res. (1995) pmid: 7775257", "Include": "true"}, {"number": "60", "ReferenceId": "11117578", "FullCitation": "Muneyuki T, et al. Dig. Dis. Sci. (2000) pmid: 11117578", "Include": "true"}, {"number": "61", "ReferenceId": "15918185", "FullCitation": "Zhang SH, et al. World J. Gastroenterol. (2005) pmid: 15918185", "Include": "true"}, {"number": "62", "ReferenceId": "14656944", "FullCitation": "Chiappini F, et al. Carcinogenesis (2004) pmid: 14656944", "Include": "true"}, {"number": "63", "ReferenceId": "11223838", "FullCitation": "Suto T, et al. J Surg Oncol (2001) pmid: 11223838", "Include": "true"}, {"number": "64", "ReferenceId": "11580146", "FullCitation": "Momoi H, et al. J. Hepatol. (2001) pmid: 11580146", "Include": "true"}, {"number": "65", "ReferenceId": "14506736", "FullCitation": "Liengswangwong U, et al. Int. J. Cancer (2003) pmid: 14506736", "Include": "true"}, {"number": "66", "ReferenceId": "25680569", "FullCitation": "Moy AP, et al. Virchows Arch. (2015) pmid: 25680569", "Include": "true"}, {"number": "67", "ReferenceId": "11063221", "FullCitation": "Yoshida T, et al. J. Gastroenterol. (2000) pmid: 11063221", "Include": "true"}, {"number": "68", "ReferenceId": "25255306", "FullCitation": "Pritchard CC, et al. Nat Commun (2014) pmid: 25255306", "Include": "true"}, {"number": "69", "ReferenceId": "17233803", "FullCitation": "Azzouzi AR, et al. BJU Int. (2007) pmid: 17233803", "Include": "true"}, {"number": "70", "ReferenceId": "16924473", "FullCitation": "Burger M, et al. J. Mol. Med. (2006) pmid: 16924473", "Include": "true"}, {"number": "71", "ReferenceId": "23690119", "FullCitation": "Bai S, et al. Am. J. Clin. Pathol. (2013) pmid: 23690119", "Include": "true"}, {"number": "72", "ReferenceId": "25319978", "FullCitation": "Giedl J, et al. Am. J. Clin. Pathol. (2014) pmid: 25319978", "Include": "true"}, {"number": "73", "ReferenceId": "16675567", "FullCitation": "Yamamoto Y, et al. Clin. Cancer Res. (2006) pmid: 16675567", "Include": "true"}, {"number": "74", "ReferenceId": "25026289", "FullCitation": "Bilbao_Sieyro C, et al. Oncotarget (2014) pmid: 25026289", "Include": "true"}, {"number": "75", "ReferenceId": "20304627", "FullCitation": "Mackay HJ, et al. Eur. J. Cancer (2010) pmid: 20304627", "Include": "true"}, {"number": "76", "ReferenceId": "19275958", "FullCitation": "Arabi H, et al. Gynecol. Oncol. (2009) pmid: 19275958", "Include": "true"}, {"number": "77", "ReferenceId": "17204026", "FullCitation": "Histopathology (2007) pmid: 17204026", "Include": "true"}, {"number": "78", "ReferenceId": "28734759", "FullCitation": "Overman MJ, et al. Lancet Oncol. (2017) pmid: 28734759", "Include": "true"}, {"number": "79", "ReferenceId": "29355075", "FullCitation": "Overman MJ, et al. J. Clin. Oncol. (2018) pmid: 29355075", "Include": "true"}, {"number": "80", "ReferenceId": "35322232", "FullCitation": "Shitara K, et al. Nature (2022) pmid: 35322232", "Include": "true"}, {"number": "81", "ReferenceId": "23169436", "FullCitation": "Lipson EJ, et al. Clin. Cancer Res. (2013) pmid: 23169436", "Include": "true"}, {"number": "82", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "83", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "84", "ReferenceId": "33001143", "FullCitation": "Oaknin A, et al. JAMA Oncol (2020) pmid: 33001143", "Include": "true"}, {"number": "85", "ReferenceId": "31602320", "FullCitation": "Li G, et al. J Gastrointest Oncol (2019) pmid: 31602320", "Include": "true"}, {"number": "86", "ReferenceId": "32757294", "FullCitation": "Zhang EW, et al. Cancer (2020) pmid: 32757294", "Include": "true"}, {"number": "87", "ReferenceId": "30833418", "FullCitation": "Butler TM, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 30833418", "Include": "true"}, {"number": "88", "ReferenceId": "24553385", "FullCitation": "Bettegowda C, et al. Sci Transl Med (2014) pmid: 24553385", "Include": "true"}, {"number": "89", "ReferenceId": "30400802", "FullCitation": "Lapin M, et al. J Transl Med (2018) pmid: 30400802", "Include": "true"}, {"number": "90", "ReferenceId": "30131550", "FullCitation": "Shulman DS, et al. Br. J. Cancer (2018) pmid: 30131550", "Include": "true"}, {"number": "91", "ReferenceId": "30385733", "FullCitation": "Choudhury AD, et al. JCI Insight (2018) pmid: 30385733", "Include": "true"}, {"number": "92", "ReferenceId": "29298117", "FullCitation": "Stover DG, et al. J. Clin. Oncol. (2018) pmid: 29298117", "Include": "true"}, {"number": "93", "ReferenceId": "30793095", "FullCitation": "Hemming ML, et al. JCO Precis Oncol (2019) pmid: 30793095", "Include": "true"}, {"number": "94", "ReferenceId": "31059681", "FullCitation": "Egyud M, et al. Ann. Thorac. Surg. (2019) pmid: 31059681", "Include": "true"}, {"number": "95", "ReferenceId": "28187169", "FullCitation": "Fan G, et al. PLoS ONE (2017) pmid: 28187169", "Include": "true"}, {"number": "96", "ReferenceId": "30923679", "FullCitation": "Bronkhorst AJ, et al. Biomol Detect Quantif (2019) pmid: 30923679", "Include": "true"}, {"number": "97", "ReferenceId": "30093454", "FullCitation": "Raja R, et al. Clin. Cancer Res. (2018) pmid: 30093454", "Include": "true"}, {"number": "98", "ReferenceId": "30860573", "FullCitation": "Hrebien S, et al. Ann. Oncol. (2019) pmid: 30860573", "Include": "true"}, {"number": "99", "ReferenceId": "28450425", "FullCitation": "Goodall J, et al. Cancer Discov (2017) pmid: 28450425", "Include": "true"}, {"number": "100", "ReferenceId": "29330207", "FullCitation": "Goldberg SB, et al. Clin. Cancer Res. (2018) pmid: 29330207", "Include": "true"}, {"number": "101", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "102", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "103", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "104", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "105", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "106", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "107", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "108", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "109", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "110", "ReferenceId": "30082870", "FullCitation": "Gandara DR, et al. Nat. Med. (2018) pmid: 30082870", "Include": "true"}, {"number": "111", "ReferenceId": "30816954", "FullCitation": "Wang Z, et al. JAMA Oncol (2019) pmid: 30816954", "Include": "true"}, {"number": "112", "ReferenceId": "32102950", "FullCitation": "Aggarwal C, et al. Clin. Cancer Res. (2020) pmid: 32102950", "Include": "true"}, {"number": "113", "ReferenceId": "27009843", "FullCitation": "Xiao D, et al. Oncotarget (2016) pmid: 27009843", "Include": "true"}, {"number": "114", "ReferenceId": "26200269", "FullCitation": "Shim HS, et al. J Thorac Oncol (2015) pmid: 26200269", "Include": "true"}, {"number": "115", "ReferenceId": "22980976", "FullCitation": "Govindan R, et al. Cell (2012) pmid: 22980976", "Include": "true"}, {"number": "116", "ReferenceId": "18948947", "FullCitation": "Ding L, et al. Nature (2008) pmid: 18948947", "Include": "true"}, {"number": "117", "ReferenceId": "22980975", "FullCitation": "Imielinski M, et al. Cell (2012) pmid: 22980975", "Include": "true"}, {"number": "118", "ReferenceId": "24323028", "FullCitation": "Kim Y, et al. J. Clin. Oncol. (2014) pmid: 24323028", "Include": "true"}, {"number": "119", "ReferenceId": "27022117", "FullCitation": "Stadler ZK, et al. J. Clin. Oncol. (2016) pmid: 27022117", "Include": "true"}, {"number": "120", "ReferenceId": "11535541", "FullCitation": "Samowitz WS, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11535541", "Include": "true"}, {"number": "121", "ReferenceId": "12445368", "FullCitation": "Elsaleh H, et al. Clin Colorectal Cancer (2001) pmid: 12445368", "Include": "true"}, {"number": "122", "ReferenceId": "12820457", "FullCitation": "Brueckl WM, et al. Anticancer Res. () pmid: 12820457", "Include": "true"}, {"number": "123", "ReferenceId": "11438476", "FullCitation": "Guidoboni M, et al. Am. J. Pathol. (2001) pmid: 11438476", "Include": "true"}, {"number": "124", "ReferenceId": "10631274", "FullCitation": "Gryfe R, et al. N. Engl. J. Med. (2000) pmid: 10631274", "Include": "true"}, {"number": "125", "ReferenceId": "16952542", "FullCitation": "Sinicrope FA, et al. Gastroenterology (2006) pmid: 16952542", "Include": "true"}, {"number": "126", "ReferenceId": "22722556", "FullCitation": "Laghi L, et al. Dig Dis (2012) pmid: 22722556", "Include": "true"}, {"number": "127", "ReferenceId": "27159395", "FullCitation": "Mehnert JM, et al. J. Clin. Invest. (2016) pmid: 27159395", "Include": "true"}, {"number": "128", "ReferenceId": "25394778", "FullCitation": "Hussein YR, et al. Mod. Pathol. (2015) pmid: 25394778", "Include": "true"}, {"number": "129", "ReferenceId": "23528559", "FullCitation": "Church DN, et al. Hum. Mol. Genet. (2013) pmid: 23528559", "Include": "true"}, {"number": "130", "ReferenceId": "24777035", "FullCitation": "Cazier JB, et al. Nat Commun (2014) pmid: 24777035", "Include": "true"}, {"number": "131", "ReferenceId": "35274716", "FullCitation": "Sturgill EG, et al. Oncologist (2022) pmid: 35274716", "Include": "true"}, {"number": "132", "ReferenceId": "32379280", "FullCitation": "Chen EX, et al. JAMA Oncol (2020) pmid: 32379280", "Include": "true"}, {"number": "133", "ReferenceId": "32271377", "FullCitation": "Rizvi NA, et al. JAMA Oncol (2020) pmid: 32271377", "Include": "true"}, {"number": "134", "ReferenceId": "33355200", "FullCitation": "Si H, et al. Clin Cancer Res (2021) pmid: 33355200", "Include": "true"}, {"number": "135", "ReferenceId": "34800700", "FullCitation": "Leighl NB, et al. J Thorac Oncol (2022) pmid: 34800700", "Include": "true"}, {"number": "136", "ReferenceId": "9860993", "FullCitation": "Hayward BE, et al. Proc. Natl. Acad. Sci. U.S.A. (1998) pmid: 9860993", "Include": "true"}, {"number": "137", "ReferenceId": "23550210", "FullCitation": "Gao J, et al. Sci Signal (2013) pmid: 23550210", "Include": "true"}, {"number": "138", "ReferenceId": "24071852", "FullCitation": "Zack TI, et al. Nat. Genet. (2013) pmid: 24071852", "Include": "true"}, {"number": "139", "ReferenceId": "20164920", "FullCitation": "Beroukhim R, et al. Nature (2010) pmid: 20164920", "Include": "true"}, {"number": "140", "ReferenceId": "2549064", "FullCitation": "Masters SB, et al. J. Biol. Chem. (1989) pmid: 2549064", "Include": "true"}, {"number": "141", "ReferenceId": "2549065", "FullCitation": "Graziano MP, et al. J. Biol. Chem. (1989) pmid: 2549065", "Include": "true"}, {"number": "142", "ReferenceId": "11322485", "FullCitation": "Jang IS, et al. Exp. Mol. Med. (2001) pmid: 11322485", "Include": "true"}, {"number": "143", "ReferenceId": "2549426", "FullCitation": "Landis CA, et al. Nature (1989) pmid: 2549426", "Include": "true"}, {"number": "144", "ReferenceId": "23288949", "FullCitation": "Tobar_Rubin R, et al. J. Mol. Endocrinol. (2013) pmid: 23288949", "Include": "true"}, {"number": "145", "ReferenceId": "20887824", "FullCitation": "Mariot V, et al. Bone (2011) pmid: 20887824", "Include": "true"}, {"number": "146", "ReferenceId": "1944469", "FullCitation": "Weinstein LS, et al. N. Engl. J. Med. (1991) pmid: 1944469", "Include": "true"}, {"number": "147", "ReferenceId": "12970318", "FullCitation": "Collins MT, et al. J. Clin. Endocrinol. Metab. (2003) pmid: 12970318", "Include": "true"}, {"number": "148", "ReferenceId": "21835143", "FullCitation": "Nault JC, et al. J. Hepatol. (2012) pmid: 21835143", "Include": "true"}, {"number": "149", "ReferenceId": "22355676", "FullCitation": "Furukawa T, et al. Sci Rep (2011) pmid: 22355676", "Include": "true"}, {"number": "150", "ReferenceId": "21775669", "FullCitation": "Wu J, et al. Sci Transl Med (2011) pmid: 21775669", "Include": "true"}, {"number": "151", "ReferenceId": "23403822", "FullCitation": "Nishikawa G, et al. Br. J. Cancer (2013) pmid: 23403822", "Include": "true"}, {"number": "152", "ReferenceId": "24925222", "FullCitation": "Singhi AD, et al. Hum. Pathol. (2014) pmid: 24925222", "Include": "true"}, {"number": "153", "ReferenceId": "30371878", "FullCitation": "Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878", "Include": "true"}, {"number": "154", "ReferenceId": "21720365", "FullCitation": "Nature (2011) pmid: 21720365", "Include": "true"}, {"number": "155", "ReferenceId": "20668451", "FullCitation": "Kan Z, et al. Nature (2010) pmid: 20668451", "Include": "true"}, {"number": "156", "ReferenceId": "20537689", "FullCitation": "Tominaga E, et al. Gynecol. Oncol. (2010) pmid: 20537689", "Include": "true"}, {"number": "157", "ReferenceId": "25079317", "FullCitation": "Nature (2014) pmid: 25079317", "Include": "true"}, {"number": "158", "ReferenceId": "25079552", "FullCitation": "Nature (2014) pmid: 25079552", "Include": "true"}, {"number": "159", "ReferenceId": "23000897", "FullCitation": "Nature (2012) pmid: 23000897", "Include": "true"}, {"number": "160", "ReferenceId": "25855536", "FullCitation": "Witkiewicz AK, et al. Nat Commun (2015) pmid: 25855536", "Include": "true"}, {"number": "161", "ReferenceId": "20601955", "FullCitation": "Barretina J, et al. Nat. Genet. (2010) pmid: 20601955", "Include": "true"}, {"number": "162", "ReferenceId": "24434212", "FullCitation": "Lohr JG, et al. Cancer Cell (2014) pmid: 24434212", "Include": "true"}, {"number": "163", "ReferenceId": "21430775", "FullCitation": "Chapman MA, et al. Nature (2011) pmid: 21430775", "Include": "true"}, {"number": "164", "ReferenceId": "21357941", "FullCitation": "Zacharin M, et al. J. Med. Genet. (2011) pmid: 21357941", "Include": "true"}, {"number": "165", "ReferenceId": "20027678", "FullCitation": "Alakus H, et al. World J. Gastroenterol. (2009) pmid: 20027678", "Include": "true"}, {"number": "166", "ReferenceId": "28868010", "FullCitation": "Ang C, et al. Case Rep Oncol () pmid: 28868010", "Include": "true"}, {"number": "167", "ReferenceId": "31740567", "FullCitation": "Saunders IM, et al. Oncologist (2019) pmid: 31740567", "Include": "true"}, {"number": "168", "ReferenceId": "19935675", "FullCitation": "Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675", "Include": "true"}, {"number": "169", "ReferenceId": "18410249", "FullCitation": "Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249", "Include": "true"}, {"number": "170", "ReferenceId": "12826609", "FullCitation": "Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609", "Include": "true"}, {"number": "171", "ReferenceId": "20978130", "FullCitation": "Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130", "Include": "true"}, {"number": "172", "ReferenceId": "28472496", "FullCitation": "Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496", "Include": "true"}, {"number": "173", "ReferenceId": "17690113", "FullCitation": "Yamada H, et al. Carcinogenesis (2007) pmid: 17690113", "Include": "true"}, {"number": "174", "ReferenceId": "24132290", "FullCitation": "Kandoth C, et al. Nature (2013) pmid: 24132290", "Include": "true"}, {"number": "175", "ReferenceId": "16537709", "FullCitation": "Wongsurawat VJ, et al. Cancer Epidemiol. Biomarkers Prev. (2006) pmid: 16537709", "Include": "true"}, {"number": "176", "ReferenceId": "19693097", "FullCitation": "Brosh R, et al. Nat. Rev. Cancer (2009) pmid: 19693097", "Include": "true"}, {"number": "177", "ReferenceId": "2649981", "FullCitation": "Baker SJ, et al. Science (1989) pmid: 2649981", "Include": "true"}, {"number": "178", "ReferenceId": "24053468", "FullCitation": "Calcagno DQ, et al. BMC Gastroenterol (2013) pmid: 24053468", "Include": "true"}, {"number": "179", "ReferenceId": "18465328", "FullCitation": "Alsner J, et al. Acta Oncol (2008) pmid: 18465328", "Include": "true"}, {"number": "180", "ReferenceId": "16489069", "FullCitation": "Olivier M, et al. Clin. Cancer Res. (2006) pmid: 16489069", "Include": "true"}, {"number": "181", "ReferenceId": "23359294", "FullCitation": "V\u00e9gran F, et al. PLoS ONE (2013) pmid: 23359294", "Include": "true"}, {"number": "182", "ReferenceId": "22678923", "FullCitation": "Wild PJ, et al. EMBO Mol Med (2012) pmid: 22678923", "Include": "true"}, {"number": "183", "ReferenceId": "20006376", "FullCitation": "Lee EJ, et al. Gynecol. Oncol. (2010) pmid: 20006376", "Include": "true"}, {"number": "184", "ReferenceId": "24107801", "FullCitation": "Ganci F, et al. Ann. Oncol. (2013) pmid: 24107801", "Include": "true"}, {"number": "185", "ReferenceId": "21467160", "FullCitation": "Lindenbergh_van der Plas M, et al. Clin. Cancer Res. (2011) pmid: 21467160", "Include": "true"}, {"number": "186", "ReferenceId": "21513535", "FullCitation": "Peltonen JK, et al. Head Neck Oncol (2011) pmid: 21513535", "Include": "true"}, {"number": "187", "ReferenceId": "9761125", "FullCitation": "Bringuier PP, et al. Int. J. Cancer (1998) pmid: 9761125", "Include": "true"}, {"number": "188", "ReferenceId": "24500328", "FullCitation": "Feng C, et al. Sci Rep (2014) pmid: 24500328", "Include": "true"}, {"number": "189", "ReferenceId": "28039262", "FullCitation": "Dong ZY, et al. Clin. Cancer Res. (2017) pmid: 28039262", "Include": "true"}, {"number": "190", "ReferenceId": "16172461", "FullCitation": "Russo A, et al. J. Clin. Oncol. (2005) pmid: 16172461", "Include": "true"}, {"number": "191", "ReferenceId": "20107315", "FullCitation": "Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315", "Include": "true"}, {"number": "192", "ReferenceId": "21799033", "FullCitation": "Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033", "Include": "true"}, {"number": "193", "ReferenceId": "21389100", "FullCitation": "Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100", "Include": "true"}, {"number": "194", "ReferenceId": "25504633", "FullCitation": "Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633", "Include": "true"}, {"number": "195", "ReferenceId": "12489850", "FullCitation": "Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850", "Include": "true"}, {"number": "196", "ReferenceId": "11713371", "FullCitation": "Xu L, et al. Mol. Med. (2001) pmid: 11713371", "Include": "true"}, {"number": "197", "ReferenceId": "23470564", "FullCitation": "Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564", "Include": "true"}, {"number": "198", "ReferenceId": "25240597", "FullCitation": "Kim SS, et al. Nanomedicine (2015) pmid: 25240597", "Include": "true"}, {"number": "199", "ReferenceId": "27357628", "FullCitation": "Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628", "Include": "true"}, {"number": "200", "ReferenceId": "27601554", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554", "Include": "true"}, {"number": "201", "ReferenceId": "27998224", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224", "Include": "true"}, {"number": "202", "ReferenceId": "31315834", "FullCitation": "Lee J, et al. Cancer Discov (2019) pmid: 31315834", "Include": "true"}, {"number": "203", "ReferenceId": "29535125", "FullCitation": "M\u00e9ndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125", "Include": "true"}, {"number": "204", "ReferenceId": "34538072", "FullCitation": "Seligmann JF, et al. J Clin Oncol (2021) pmid: 34538072", "Include": "true"}, {"number": "205", "ReferenceId": "36084396", "FullCitation": "Park H, et al. ESMO Open (2022) pmid: 36084396", "Include": "true"}, {"number": "206", "ReferenceId": "26014290", "FullCitation": "Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290", "Include": "true"}, {"number": "207", "ReferenceId": "23355100", "FullCitation": "Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100", "Include": "true"}, {"number": "208", "ReferenceId": "11219776", "FullCitation": "Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776", "Include": "true"}, {"number": "209", "ReferenceId": "9006316", "FullCitation": "Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316", "Include": "true"}, {"number": "210", "ReferenceId": "19204208", "FullCitation": "Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208", "Include": "true"}, {"number": "211", "ReferenceId": "12672316", "FullCitation": "Lalloo F, et al. Lancet (2003) pmid: 12672316", "Include": "true"}, {"number": "212", "ReferenceId": "31050713", "FullCitation": "Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713", "Include": "true"}, {"number": "213", "ReferenceId": "25426837", "FullCitation": "Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837", "Include": "true"}, {"number": "214", "ReferenceId": "25426838", "FullCitation": "Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838", "Include": "true"}, {"number": "215", "ReferenceId": "25326804", "FullCitation": "Xie M, et al. Nat. Med. (2014) pmid: 25326804", "Include": "true"}, {"number": "216", "ReferenceId": "28669404", "FullCitation": "Acuna_Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404", "Include": "true"}, {"number": "217", "ReferenceId": "29678827", "FullCitation": "Severson EA, et al. Blood (2018) pmid: 29678827", "Include": "true"}, {"number": "218", "ReferenceId": "29420212", "FullCitation": "Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212", "Include": "true"}, {"number": "219", "ReferenceId": "30504320", "FullCitation": "Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320", "Include": "true"}, {"number": "220", "ReferenceId": "32269342", "FullCitation": "Chabon JJ, et al. Nature (2020) pmid: 32269342", "Include": "true"}, {"number": "221", "ReferenceId": "31768066", "FullCitation": "Razavi P, et al. Nat. Med. (2019) pmid: 31768066", "Include": "true"}, {"number": "222", "ReferenceId": "25344362", "FullCitation": "Tolcher AW, et al. Ann. Oncol. (2015) pmid: 25344362", "Include": "true"}, {"number": "223", "ReferenceId": "22805291", "FullCitation": "Infante JR, et al. Lancet Oncol. (2012) pmid: 22805291", "Include": "true"}, {"number": "224", "ReferenceId": "22767668", "FullCitation": "Leijen S, et al. Clin. Cancer Res. (2012) pmid: 22767668", "Include": "true"}, {"number": "225", "ReferenceId": "24947927", "FullCitation": "Zimmer L, et al. Clin. Cancer Res. (2014) pmid: 24947927", "Include": "true"}, {"number": "226", "ReferenceId": "23583440", "FullCitation": "Infante JR, et al. Eur. J. Cancer (2013) pmid: 23583440", "Include": "true"}, {"number": "227", "ReferenceId": "28339824", "FullCitation": "Banerjee A, et al. Neuro_oncology (2017) pmid: 28339824", "Include": "true"}, {"number": "228", "ReferenceId": "24567366", "FullCitation": "Gupta A, et al. Ann. Oncol. (2014) pmid: 24567366", "Include": "true"}, {"number": "229", "ReferenceId": "23735514", "FullCitation": "Robert C, et al. Lancet Oncol. (2013) pmid: 23735514", "Include": "true"}, {"number": "230", "ReferenceId": "22048237", "FullCitation": "Kirkwood JM, et al. Clin. Cancer Res. (2012) pmid: 22048237", "Include": "true"}, {"number": "231", "ReferenceId": "20179232", "FullCitation": "Banerji U, et al. Clin. Cancer Res. (2010) pmid: 20179232", "Include": "true"}, {"number": "232", "ReferenceId": "22293660", "FullCitation": "Boers_Sonderen MJ, et al. Anticancer Drugs (2012) pmid: 22293660", "Include": "true"}, {"number": "233", "ReferenceId": "25667274", "FullCitation": "Lopez_Chavez A, et al. J. Clin. Oncol. (2015) pmid: 25667274", "Include": "true"}, {"number": "234", "ReferenceId": "20802351", "FullCitation": "Hainsworth JD, et al. J Thorac Oncol (2010) pmid: 20802351", "Include": "true"}, {"number": "235", "ReferenceId": "25887099", "FullCitation": "Coleman RL, et al. Gynecol. Oncol. (2015) pmid: 25887099", "Include": "true"}, {"number": "236", "ReferenceId": "35363510", "FullCitation": "Eckstein OS, et al. J Clin Oncol (2022) pmid: 35363510", "Include": "true"}, {"number": "237", "ReferenceId": "26666244", "FullCitation": "Deming DA, et al. Invest New Drugs (2016) pmid: 26666244", "Include": "true"}, {"number": "238", "ReferenceId": "30042150", "FullCitation": "Krishnamurthy A, et al. Cancer Res. (2018) pmid: 30042150", "Include": "true"}, {"number": "239", "ReferenceId": "28424891", "FullCitation": "Infante JR, et al. Invest New Drugs (2017) pmid: 28424891", "Include": "true"}, {"number": "240", "ReferenceId": "28264648", "FullCitation": "LoRusso PM, et al. BMC Cancer (2017) pmid: 28264648", "Include": "true"}, {"number": "241", "ReferenceId": "25516890", "FullCitation": "Tolcher AW, et al. Clin. Cancer Res. (2015) pmid: 25516890", "Include": "true"}, {"number": "242", "ReferenceId": "25268371", "FullCitation": "Wilky BA, et al. Br. J. Cancer (2015) pmid: 25268371", "Include": "true"}, {"number": "243", "ReferenceId": "26566875", "FullCitation": "Diamond EL, et al. Cancer Discov (2016) pmid: 26566875", "Include": "true"}, {"number": "244", "ReferenceId": "30867592", "FullCitation": "Diamond EL, et al. Nature (2019) pmid: 30867592", "Include": "true"}, {"number": "245", "ReferenceId": "29236635", "FullCitation": "Jacobsen E, et al. N. Engl. J. Med. (2017) pmid: 29236635", "Include": "true"}, {"number": "246", "ReferenceId": "35372654", "FullCitation": "Berce PC, et al. JAAD Case Rep (2022) pmid: 35372654", "Include": "true"}, {"number": "247", "ReferenceId": "32823478", "FullCitation": "Giuffr\u00e8 C, et al. Indian J Ophthalmol (2020) pmid: 32823478", "Include": "true"}, {"number": "248", "ReferenceId": "31376269", "FullCitation": "Razanamahery J, et al. Clin Exp Rheumatol () pmid: 31376269", "Include": "true"}, {"number": "249", "ReferenceId": "31669429", "FullCitation": "Moyon Q, et al. Chest (2020) pmid: 31669429", "Include": "true"}, {"number": "250", "ReferenceId": "36135991", "FullCitation": "Gupta RK, et al. Neurol Int (2022) pmid: 36135991", "Include": "true"}, {"number": "251", "ReferenceId": "27424159", "FullCitation": "Rosen LS, et al. Invest New Drugs (2016) pmid: 27424159", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2022_12_13 04:47:54", "OpName": "Nimesh Patel, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Nimesh Patel, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "N/A"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "4 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "0%"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease_ontology": "Unknown primary carcinoma (NOS)", "flowcell_analysis": "2000025865", "gender": "male", "pathology_diagnosis": "HPV_positive carcinoma", "pipeline_version": "v3.16.0", "purity_assessment": "30.5", "specimen": "ORD_1517889_01*US1452511.01", "study": "CLINICAL_F1LCDx", "test_request": "ORD_1517889_01", "test_type": "FoundationOneLiquidDx", "tissue_of_origin": "Blood", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "AB1", "name": "SQ_US1452511.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.0099", "cds_effect": "2033_2034insC", "depth": "4459", "equivocal": "false", "functional_effect": "frameshift", "gene": "NF1", "percent_reads": "0.99", "position": "chr17:29553484", "protein_effect": "I679fs*21", "status": "known", "strand": "+", "transcript": "NM_001042492", "dna_evidence": {"sample": "SQ_US1452511.01_1"}}, {"allele_fraction": "0.0055", "cds_effect": "2723G>T", "depth": "2193", "equivocal": "false", "functional_effect": "missense", "gene": "CREBBP", "percent_reads": "0.55", "position": "chr16:3820728", "protein_effect": "S908I", "status": "unknown", "strand": "_", "transcript": "NM_004380", "dna_evidence": {"sample": "SQ_US1452511.01_1"}}, {"allele_fraction": "0.0055", "cds_effect": "733G>A", "depth": "5473", "equivocal": "false", "functional_effect": "missense", "gene": "TP53", "percent_reads": "0.55", "position": "chr17:7577548", "protein_effect": "G245S", "status": "known", "strand": "_", "transcript": "NM_000546", "dna_evidence": {"sample": "SQ_US1452511.01_1"}}, {"allele_fraction": "0.489", "cds_effect": "688T>C", "depth": "1908", "equivocal": "false", "functional_effect": "missense", "gene": "CD22", "percent_reads": "48.9", "position": "chr19:35827214", "protein_effect": "S230P", "status": "unknown", "strand": "+", "transcript": "NM_001771", "dna_evidence": {"sample": "SQ_US1452511.01_1"}}, {"allele_fraction": "0.5087", "cds_effect": "317A>G", "depth": "5779", "equivocal": "false", "functional_effect": "missense", "gene": "PDCD1LG2", "percent_reads": "50.87", "position": "chr9:5535006", "protein_effect": "Y106C", "status": "unknown", "strand": "+", "transcript": "NM_025239", "dna_evidence": {"sample": "SQ_US1452511.01_1"}}, {"allele_fraction": "1.0", "cds_effect": "2081C>T", "depth": "1517", "equivocal": "false", "functional_effect": "missense", "gene": "CARD11", "percent_reads": "100.0", "position": "chr7:2962827", "protein_effect": "S694L", "status": "unknown", "strand": "_", "transcript": "NM_032415", "dna_evidence": {"sample": "SQ_US1452511.01_1"}}, {"allele_fraction": "0.5095", "cds_effect": "233_234TC>CT", "depth": "422", "equivocal": "false", "functional_effect": "missense", "gene": "MAP3K1", "percent_reads": "50.95", "position": "chr5:56111633", "protein_effect": "L78P", "status": "unknown", "strand": "+", "transcript": "NM_005921", "dna_evidence": {"sample": "SQ_US1452511.01_1"}}, {"allele_fraction": "0.0016", "cds_effect": "1405C>T", "depth": "6420", "equivocal": "false", "functional_effect": "missense", "gene": "FGFR1", "percent_reads": "0.16", "position": "chr8:38275771", "protein_effect": "P469S", "status": "unknown", "strand": "_", "transcript": "NM_023110", "dna_evidence": {"sample": "SQ_US1452511.01_1"}}, {"allele_fraction": "0.0043", "cds_effect": "7C>A", "depth": "1401", "equivocal": "false", "functional_effect": "missense", "gene": "FGF6", "percent_reads": "0.43", "position": "chr12:4554730", "protein_effect": "L3M", "status": "unknown", "strand": "_", "transcript": "NM_020996", "dna_evidence": {"sample": "SQ_US1452511.01_1"}}, {"allele_fraction": "0.4967", "cds_effect": "3374T>C", "depth": "6992", "equivocal": "false", "functional_effect": "missense", "gene": "APC", "percent_reads": "49.67", "position": "chr5:112174665", "protein_effect": "V1125A", "status": "unknown", "strand": "+", "transcript": "NM_000038", "dna_evidence": {"sample": "SQ_US1452511.01_1"}}, {"allele_fraction": "0.0048", "cds_effect": "183T>A", "depth": "1674", "equivocal": "false", "functional_effect": "missense", "gene": "EPHA3", "percent_reads": "0.48", "position": "chr3:89259039", "protein_effect": "H61Q", "status": "unknown", "strand": "+", "transcript": "NM_005233", "dna_evidence": {"sample": "SQ_US1452511.01_1"}}, {"allele_fraction": "0.0053", "cds_effect": "1639G>A", "depth": "1890", "equivocal": "false", "functional_effect": "missense", "gene": "NTRK3", "percent_reads": "0.53", "position": "chr15:88483931", "protein_effect": "G547R", "status": "unknown", "strand": "_", "transcript": "NM_002530", "dna_evidence": {"sample": "SQ_US1452511.01_1"}}, {"allele_fraction": "0.5047", "cds_effect": "2399A>T", "depth": "5393", "equivocal": "false", "functional_effect": "missense", "gene": "EGFR", "percent_reads": "50.47", "position": "chr7:55249101", "protein_effect": "D800V", "status": "unknown", "strand": "+", "transcript": "NM_005228", "dna_evidence": {"sample": "SQ_US1452511.01_1"}}, {"allele_fraction": "0.5175", "cds_effect": "1955G>A", "depth": "5869", "equivocal": "false", "functional_effect": "missense", "gene": "PALB2", "percent_reads": "51.75", "position": "chr16:23641520", "protein_effect": "S652N", "status": "unknown", "strand": "_", "transcript": "NM_024675", "dna_evidence": {"sample": "SQ_US1452511.01_1"}}, {"allele_fraction": "0.0025", "cds_effect": "602G>A", "depth": "4779", "equivocal": "false", "functional_effect": "missense", "gene": "GNAS", "percent_reads": "0.25", "position": "chr20:57484421", "protein_effect": "R201H", "status": "known", "strand": "+", "transcript": "NM_000516", "dna_evidence": {"sample": "SQ_US1452511.01_1"}}, {"allele_fraction": "0.4723", "cds_effect": "1534G>A", "depth": "902", "equivocal": "false", "functional_effect": "missense", "gene": "IRS2", "percent_reads": "47.23", "position": "chr13:110436867", "protein_effect": "A512T", "status": "unknown", "strand": "_", "transcript": "NM_003749", "dna_evidence": {"sample": "SQ_US1452511.01_1"}}]}, "copy_number_alterations": null, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "3.79", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": {"non_human": [{"organism": "HPV_16", "reads_per_million": "35", "status": "unknown", "dna_evidence": {"sample": "SQ_US1452511.01_1"}}, {"organism": "HHV_8", "reads_per_million": "24", "status": "unknown", "dna_evidence": {"sample": "SQ_US1452511.01_1"}}, {"organism": "HHV_4", "reads_per_million": "56", "status": "unknown", "dna_evidence": {"sample": "SQ_US1452511.01_1"}}]}}}}}